Cell Viability Assays Market Size, Share, Industry Trends and Forecast to 2030

1. What is the Market Size & CAGR of Cell Viability Assays market in 2021?

The global cell viability assays market had a market size of USD 3.5 billion in 2021, with a Compound Annual Growth Rate (CAGR) of 8.2% during the forecast period from 2021 to 2026. The increasing focus on drug discovery and development, along with the rising incidence of chronic diseases, is driving the growth of the cell viability assays market.

2. COVID-19 Impact on the Cell Viability Assays Market

The COVID-19 pandemic has significantly impacted the cell viability assays market. The disruptions in supply chains, delayed clinical trials, and reduced research and development activities have had a negative effect on the market. However, the increased focus on developing antiviral drugs and vaccines has created new opportunities for growth in the market.

3. Cell Viability Assays Dynamics

The cell viability assays market is driven by factors such as the increasing adoption of 3D cell culture models, advancements in imaging technologies, and the rising demand for personalized medicine. However, challenges such as high costs associated with assays and the lack of skilled professionals may hinder market growth.

4. Segments and Related Analysis

4.1 Drug Type:

- Fluorescent Assays
- Colorimetric Assays
- Luminescent Assays

4.2 Application:

- Drug Discovery
- Stem Cell Research
- Oncology

4.3 End User:

- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations

5. By Region Analysis

5.1 North America

The North American region is expected to dominate the cell viability assays market due to the presence of key market players, a well-established healthcare infrastructure, and increasing research and development activities in the region.

5.2 Europe

Europe is projected to witness significant growth in the cell viability assays market, attributed to the growing adoption of advanced technologies and increasing investments in drug discovery and development.

5.3 Asia Pacific

The Asia Pacific region is anticipated to register rapid growth in the cell viability assays market due to the rising prevalence of chronic diseases, expanding pharmaceutical industry, and growing research collaborations in the region.

6. Key Market Players and Competitive Landscape

- Thermo Fisher Scientific
- Merck KGaA
- Promega Corporation
- Bio-Rad Laboratories
- PerkinElmer, Inc.
- Abcam plc
- Becton, Dickinson and Company
- GE Healthcare
- Biotium

7. Recent Happenings in the Cell Viability Assays Market

- Thermo Fisher Scientific launched a new cell viability assay kit with improved sensitivity and accuracy for drug screening applications.
- Merck KGaA announced a strategic partnership with a leading biotech company to develop innovative cell viability assays for oncology research.
- Promega Corporation introduced a novel luminescent cell viability assay for high-throughput screening in drug discovery.